drugset / Trial / NCT00779064
BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is a clinical study investigating pharmacokinetics, pharmacodynamic effects and safety of BAY 59-7939 in patients with atrial fibrillation (originally described in Japanese).
Timeline
- Start
- 2004-07
- Primary completion
- 2005-06
- Completion
- 2005-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivaroxaban | Other / unclassified | 10 mg | — |
| Subject | Rivaroxaban | Other / unclassified | 20 mg | — |